BIOCRYST PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch · last filed 2026-02-26
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2025 was 0.00%.
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2024 was -2.00%.
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2023 was -1.00%.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent 12 month |
|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-02-26 |
| 2024-12-31 | -2.00% 10-K · filed 2026-02-26 |
| 2023-12-31 | -1.00% 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |